Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022
Pneumagen to present on further significant development for its lead product, Neumifil at BioTrinity 2022
St Andrews, UK – 13 April 2022 - Pneumagen, a clinical stage pharmaceutical company developing Neumifil, a first in class pan-antiviral for the prevention, treatment and management of viral induced respiratory infections is pleased to announce that its CEO, Douglas Thomson, will present at this year’s BioTrinity during a session focused on scientific updates in Infectious Diseases.
Presentation details
Date: Wednesday, 27th April 2022
Time: 15:10pm BST
Location: 155 Bishopsgate, London
Douglas Thomson will provide an overview of the company and the clinical advancement of its lead, self-administered intranasal product Neumifil, being developed for the treatment of a broad range of viral respiratory tract infections such as influenza, respiratory syncytial virus (RSV) and coronaviruses including SARS-CoV-2. Neumifil is currently in a Phase 1 clinical trial with top line results expected in the first half of 2022.
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506
